Compare Nuvalent Inc (NUVL) vs TransMedics Group Inc (TMDX) Price & Performance

Nuvalent IncTrade

TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

Nuvalent Inc vs TransMedics Group Inc — how do they compare? Nuvalent Inc trades at $123.96 (market cap $9.81B), while TransMedics Group Inc trades at $74.3 (market cap $2.54B). The key difference: Nuvalent Inc is far larger — about 3.9× TransMedics Group Inc's market cap, and Nuvalent Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.

	NUVL	TMDX
Market Cap	$9.81B	$2.54B
Sector	Technology	Technology
52-Week High	$123.96	$150.42
52-Week Low	$72.16	$61.99
Enterprise Value	$8.52B	$2.94B

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NUVL

Brodsky & Smith investigates fiduciary duty breaches in multiple major merger deals.GlobeNewsWire · 10 hours agoBearish View details →

TMDX

TransMedics to report Q2 2026 financial results on August 4 with a live conference call.PRNewsWire · 5 hours agoNeutral Atlas Healthcare Fund's 2020 Eli Lilly bet soared 246%, showcasing early clinical insight in healthcare investing.Vst Capital · 4 days agoBullish View details →

About Nuvalent Inc

Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.